文献速递神经肌肉病

确立感觉神经元为多聚谷氨酰胺扩展小鼠ATXN3所致周围神经病的治疗靶点

Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3
RSS 订阅 · Annals of Neurology · 2026-10-22

研究利用脊髓小脑性共济失调3型(SCA3)敲入Atxn3 Q300/Q6小鼠,发现其出现进行性感觉运动缺陷、周围神经病理及背根神经节RNA剪接失调;Atxn3敲除小鼠功能正常,支持毒性功能获得机制;感觉神经元特异性沉默突变ATXN3可改善神经病变及分子缺陷。

要点

  • SCA3敲入小鼠出现进行性感觉运动缺陷、周围神经病理和背根神经节RNA剪接失调。
  • Atxn3敲除小鼠周围神经功能正常,提示突变ATXN3的毒性功能获得是致病驱动因素。
  • 感觉神经元特异性沉默突变ATXN3可显著改善周围神经异常和背根神经节剪接失调。

核心结论

  • 这些发现定义了重复扩增驱动的周围神经变性在SCA3中的致病作用,将感觉神经元确定为关键治疗靶点,并为SCA3及相关重复扩增疾病的外周干预提供临床前平台。

研究设计与样本

  • 研究使用SCA3敲入Atxn3 Q300/Q6(KI)小鼠和Atxn3敲除(KO)小鼠进行感觉运动神经传导和行为测试,评估周围组织SCA3相关病理,并通过bulk RNA测序评估KI背根神经节转录变化。
  • 为测试治疗相关性,研究者构建条件性「关闭」SCA3敲入(cKI)小鼠并与Avil-Cre杂交以选择性沉默感觉神经元中的突变ATXN3,在Avil-Cre; cKI小鼠中重复外周表型分析。

主要发现

  • KI小鼠出现进行性感觉运动缺陷、周围组织病理学和RNA剪接失调,与SCA3临床特征平行。
  • KO小鼠显示正常周围神经功能,提示突变ATXN3的毒性功能获得是致病驱动因素。
  • 感觉神经元特异性沉默突变ATXN3显著改善周围神经异常和背根神经节剪接失调。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Repeat expansion disorders frequently involve peripheral neuropathy, yet mechanisms remain unclear. Using a spinocerebellar ataxia type 3 (SCA3) Knock-In Atxn3 Q300/Q6 , we identify progressive sensorimotor deficits, peripheral nerve pathology, and dorsal root ganglia RNA splicing dysregulation. Atxn3 −/− Knock-Out mice show normal function, supporting a toxic gain-of-function mechanism. Sensory neuron-specific silencing of mutant ATXN3 ameliorates neuropathy and molecular defects. These findings establish a robust model of SCA3 peripheral neuropathy and highlight sensory neurons as promising therapeutic targets for repeat expansion diseases. Objective Repeat expansion mutations underlie diverse neurogenetic disorders, many involving the peripheral nervous system. Despite peripheral neuropathy being the most common neurological disorder worldwide, its contribution to repeat expansion diseases remains poorly defined, and robust preclinical models are limited. We established a translational framework to study peripheral neuropathy in spinocerebellar ataxia type 3 (SCA3), a fatal multisystem disorder caused by a pathogenic CAG expansion in ATXN3. Methods SCA3 Knock-In Atxn3 Q300/Q6 (KI) and Atxn3 −/− Knock-Out (KO) mice underwent sensorimotor nerve conduction and behavioral testing. Peripheral tissues were evaluated for SCA3-related pathology, and transcriptional changes in KI dorsal root ganglia (DRG) were assessed by bulk RNA sequencing. To test therapeutic relevance, we generated a conditional “OFF” SCA3 knock-in (cKI) mouse and crossed it with Avil-Cre to selectively silence mutant ATXN3 in sensory neurons. Peripheral phenotyping was repeated in Avil-Cre; cKI mice. Results KI mice developed progressive sensorimotor deficits, peripheral histopathology, and RNA splicing dysregulation that parallel clinical features of SCA3. In contrast, KO mice showed normal peripheral nerve function, implicating toxic gain-of-function from mutant ATXN3 as the causative driver. Sensory neuron–specific silencing of mutant ATXN3 significantly ameliorated peripheral nerve abnormalities and DRG splicing dysregulation. Interpretation These findings define a pathogenic role for repeat expansion–driven peripheral nerve degeneration in SCA3, identify sensory neurons as key therapeutic targets, and provide a preclinical platform for developing peripheral interventions in SCA3 and related repeat expansion disorders. ANN NEUROL 2026;100:1039–1054

来源:Annals of Neurology,查看原文。版权归原作者所有。

引用

  1. Annals of Neurology:Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。